← Back to Clinical Trials
Recruiting NCT06432582

NCT06432582 hepatomiR cACLD Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06432582
Status Recruiting
Phase
Sponsor Karl Landsteiner University of Health Sciences
Condition Chronic Liver Disease and Cirrhosis
Study Type OBSERVATIONAL
Enrollment 156 participants
Start Date 2024-05-15
Primary Completion 2026-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
hepatomiR

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 156 participants in total. It began in 2024-05-15 with a primary completion date of 2026-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study looks to gather data on hepatomiR, a CE-certified test already intended for gauging liver-related outcomes, in order to define a cut-off regarding specific decompensation events (ascites, variceal hemorrhage, hepatic encephalopathy) in chronic liver disease (CLD). Based on these data, it is aimed to advance the current understanding of factors driving decompensation, with potential repercussions for future risk management and therapy.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 18 years * Chronic liver disease (more than 6 months) * LSM ≥ 10 kPa * Outpatient at the Clinical Department of Internal Medicine II, University Hospital St. Pölten * Signed patient consent form Exclusion Criteria: * Age older than 18 years * Pregnancy * Primary hepatic malignancy (hepatocellular carcinoma, cholangiocarcinoma) with portal invasion and/or extrahepatic spread

Contact & Investigator

Central Contact

Lukas Erhart, Mag. Dr.

✉ lukas.erhart@stpoelten.lknoe.at

📞 00432742900412311

Principal Investigator

Andreas Maieron, PD Dr.

PRINCIPAL INVESTIGATOR

Karl Landsteiner University of Health Sciences

Frequently Asked Questions

Who can join the NCT06432582 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Liver Disease and Cirrhosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06432582 currently recruiting?

Yes, NCT06432582 is actively recruiting participants. Contact the research team at lukas.erhart@stpoelten.lknoe.at for enrollment information.

Where is the NCT06432582 trial being conducted?

This trial is being conducted at Sankt Pölten, Austria.

Who is sponsoring the NCT06432582 clinical trial?

NCT06432582 is sponsored by Karl Landsteiner University of Health Sciences. The principal investigator is Andreas Maieron, PD Dr. at Karl Landsteiner University of Health Sciences. The trial plans to enroll 156 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology